NCT07604467 The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
| NCT ID | NCT07604467 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Centre Ljubljana |
| Condition | Tako Tsubo Cardiomyopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-09-06 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2021-09-06 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.
Eligibility Criteria
Inclusion Criteria: * Minimum age 18 years * Established TTS per InterTak registry criteria * Signed consent form Exclusion Criteria: * Patients under the age of 18 years * Ischemic heart disease with at least one complete total occlusion * Other concurrent cardiomyopathies * Active infectious myocarditis * obstructive coronary artery disease * Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event * Previous interventional coronary artery procedure in the last 6 months before TTS acute event * Significant valvular heart disease * Significant peripheral artery occlusive disease * Active or remitted hematologic malignancy * Patients receiving immunosuppressive therapy * Significant comorbiditeis affecting patients survival (malignancy) * Failure to obtain freely given, informed consent form.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07604467 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tako Tsubo Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07604467 currently recruiting?
Yes, NCT07604467 is actively recruiting participants. Contact the research team at mark.jovanovic@kclj.si for enrollment information.
Where is the NCT07604467 trial being conducted?
This trial is being conducted at Ljubljana, Slovenia.
Who is sponsoring the NCT07604467 clinical trial?
NCT07604467 is sponsored by University Medical Centre Ljubljana. The trial plans to enroll 40 participants.